In recent times, an increase in lawsuits against the Food and Drug Administration (FDA) has been observed. Frequently, clients express concern before filing such a lawsuit about potential retaliation from the FDA, such as delayed review times or increased scrutiny during application processes.
Their worries are not unfounded, considering the complex and significant weight of FDA’s decisions. However, existing evidence suggests that these apprehensions are mostly unfounded. The FDA understands the intricate nature of its decisions, and ostensibly maintains a rather impartial stance, refraining from adverse actions in response to lawsuits.
Despite the significant increase in lawsuits against the FDA recently, it appears that the administration continues to carry out its tasks efficiently and without visible bias. While the inherent apprehension of litigation with such a powerful agency is understandable, previous instances have proved that such fear of retaliation from the agency might not be entirely warranted.
It’s important for industries and businesses to recognize this, acknowledging the FDA’s role in establishing regulations that ensure public health and safety. This understanding can effectively channel communication between the industry and the FDA, hopefully reducing unnecessary litigation while also ensuring that any necessary disputes are efficiently resolved.
For more in-depth information, the article “One Too Many Suits Against FDA?” by Axinn, Veltrop & Harkrider LLP provides a comprehensive overview of this topic.